Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP

Capital International Investors grew its position in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) by 30.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,402,529 shares of the company’s stock after purchasing an additional 800,000 shares during the quarter. Capital International Investors owned about 9.32% of Rapport Therapeutics worth $101,055,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Rapport Therapeutics by 86.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after buying an additional 4,582 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC acquired a new position in shares of Rapport Therapeutics during the 1st quarter valued at $2,039,000. Rhumbline Advisers lifted its position in shares of Rapport Therapeutics by 40.1% during the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock valued at $144,000 after acquiring an additional 4,109 shares during the period. Geode Capital Management LLC boosted its stake in Rapport Therapeutics by 5.5% during the second quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock worth $3,789,000 after acquiring an additional 17,496 shares in the last quarter. Finally, Creative Planning bought a new position in Rapport Therapeutics during the second quarter worth $121,000.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RAPP. HC Wainwright upped their target price on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a report on Monday. Finally, BTIG Research upped their target price on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a report on Monday. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, insider Krishnaswamy Yeleswaram sold 2,840 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $30.05, for a total value of $85,342.00. Following the sale, the insider directly owned 296,991 shares in the company, valued at $8,924,579.55. The trade was a 0.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Abraham Ceesay sold 5,083 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $29.36, for a total value of $149,236.88. Following the transaction, the chief executive officer directly owned 20,729 shares in the company, valued at $608,603.44. This represents a 19.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 69,669 shares of company stock worth $1,999,877. Company insiders own 13.57% of the company’s stock.

Rapport Therapeutics Trading Up 3.1%

Shares of RAPP opened at $30.54 on Thursday. The stock has a 50 day moving average of $28.14 and a 200 day moving average of $26.89. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.68 and a beta of 1.51. Rapport Therapeutics, Inc. has a 12 month low of $7.73 and a 12 month high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). As a group, equities research analysts predict that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Wells Fargo raised its price target to $46 and kept an “overweight” rating, highlighting upside (~50.6% from the referenced price) and likely contributing to bullish sentiment. Benzinga
• Positive Sentiment: H.C. Wainwright reiterated a Buy and set a $40 price target, citing RAP‑219 program progress and 2026 catalysts — another analyst vote of confidence supporting the rally. TipRanks
• Positive Sentiment: Rapport announced a strategic collaboration and license with Tenacia Biotechnology to develop and commercialize RAP‑219 in Greater China — the deal adds regional commercialization optionality and non‑dilutive funding potential (coverage referenced as a multi‑hundred million biobucks structure). FinanzNachrichten
• Positive Sentiment: Company FYE results and business update: RAP‑219 showed robust Phase 2a activity, Phase 3 initiation is expected in Q2 2026, pipeline expansion (PGTCS, bipolar mania) continues, and cash of ~$490.5M is expected to fund operations into H2 2029 — this reduces financing risk and supports valuation. GlobeNewswire
• Neutral Sentiment: COO Cheryl Gault sold ~2,014 shares (small, ~1.17% reduction of her position) — routine insider selling but disclosed; investors may note timing/size but it’s not large enough to materially change ownership structure. SEC filing
• Negative Sentiment: Reported quarterly EPS of ($0.72) missed consensus of ($0.65), a short‑term negative on earnings momentum that could temper sentiment until Phase 3 execution and trial readouts provide fresh catalysts. Press release / results

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.